

Revolutionizing the way we discover drugs by understanding complex biology

Dr. eng. Kinga Matuła
CEO

Market pull

Lack of understanding of complex biology

ADURO BIOTECH™

Ibrutinib: B cell cancer malignancy treatment

"We need a technology that will allow us to **look inside the cells** and see in **high-resolution** what is happening"

Drug development: slower and more expensive

10-15 years

$1–2 billion

90% failure rate

Eroom's law



AI-powered drug development



CAGR 42%

Our solution: high-resolution maps of cellular responses

Underground network

Cellular network



QuRIE-seq quantifies intracellular interactions

10x GENOMICS

isoplexis / FLUIDIGM

QurieGen









Patent-pending,
know-how + trade secrets

Value to pharma companies

10x more insights

than 1 year of work by an internal R&D team at a **lower cost** and **less time**



Pharma case studies



Acerta Pharma
A member of the AstraZeneca Group

janssen
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

van Buijtenen E, et al. Molecular & ***Cellular Proteomics*** (2023) 22(2)

Previously **unidentified role** of **JAK1** in the BCR response

JAK1 + BTK: new opportunity for combination therapy

ADURO BIOTECH

Rivello F, et al. ***Cell Reports Methods*** (2021) 1: 100070.

One-stop service for pharma companies

QuRIE-seq platform (TRL 6/7) + data analysis



De-risk and accelerate drug development

- Find **new drug targets/ combinations**
- Select **lead compounds**
- Identify unwanted **toxicity** and **nonresponsive cells** sooner
- Detect potential **reasons for failing**
- Identify **off-target** effects
- Detect a **resistant** subset of cells

Business model: two sub-models

CRO/Pharmatech: B2B



Service and discovery partnerships

First revenue, partner and co-develop drugs

Internal pipelines

Identify novel drug targets and novel drug combinations

Big discoveries using AI

Selection of “winner” drug

Drug repurposing

Development of new drugs (our IP)

$1M

Project size

$1B

AI-driven drug discovery

Network response

Cell-type specific

Follow changes in time

The pattern of changes
is modulated by drug molecules



Observed network response in patient cells

HIDDEN LAYER of protein and mRNA networks (KEGG database +…+ **QurieGen Database**)

Desired network response of healthy cells

Business model: dual revenue stream

AI-driven drug discovery

Service-based model



The industrial revolution of drug discovery

- Data mining
- Prediction of new targets
- AI-driven development: CAGR of 42.3%

RECURSION pharmaceuticals — Valuation: $3.5B

Benevolent AI — Valuation: $1B

insitro — Investment: $400M

Cellarity, A Flagship Pioneering Company — Investment: $123M

zebi AI — Sold: $85M (5 years after founding)

Missing:

Quantitative data on intracellular (phospho)proteins and mRNA



Single-cell data

Dynamics

Exscientia: six molecules entered clinical stage

Exscientia announced **First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials**

*"(…) Where it might have taken the traditional discovery process **4–5 years to come up with the drug candidate** - an A2 receptor antagonist designed to help T cells fight solid tumors - it was found in **8 months** by harnessing Exscientia's 'Centaur Chemist' AI design platform." (1)*

(1) https://www.nature.com/articles/d43747-021-00045-7

Core team

Dr. eng. Kinga Matuła
CEO, co-founder

Biotechnologist,
Single-cell expert

>13 years of research

Prof. dr. Wilhelm Huck
Scientific Advisor

Chemist
Serial entrepreneur
Spinoza Prize and Groeifonds Winner (€100M)

>30 years of research

Jasper Levink, ir
Business & Strategy, Board Member

Serial entrepreneur
Expertise in spin-outs and scale-ups

>13 years of business experience

Dr. Hans van Eenennaam
Business and Scientific Advisor

Biochemist, Immunologist
Serial entrepreneur
Co-inventor of 5 drugs (i.a. Keytruda),

>30 years of experience in pharma R&D

Dr. Paul Vink
Research Advisor

(Onco)Immunologist
Co-inventor of 4 drugs

>30 years of experience in pharma R&D

Head of AI team
R&D

Discussions in progress
proven track record in pharma AI-driven drug discovery

venture challenge
Venture Challenge Winner 2022

DRAPER UNIVERSITY
LUMO LABS
Draper's Silicon Prize Winner 2022

DRAPER VENTURE NETWORK
2nd place Demo Day by Tim Draper 2022

DEEP TECH
hello tomorrow
Hello Tomorrow 2022 Deep Tech Pioneer